| 30.07 13:37 | dpa-AFX: Keytruda läuft: Merck & Co schlägt Erwartungen - Umsatzausblick optimistischer |
| 30.07 13:37 | Keytruda läuft: Merck & Co schlägt Erwartungen - Umsatzausblick optimistischer |
| 30.07 13:32 | dpa-AFX: Keytruda läuft: Merck & Co schlägt Erwartungen - Umsatzausblick optimistischer |
| 30.07 12:57 | dpa-AFX: Merck Q2 Results Beat Estimates; Cuts FY24 Adj. EPS View, Lifts Sales Forecast |
| 30.07 12:47 | dpa-AFX: *MERCK & CO VORBÖRSLICH -1,5% NACH QUARTALSZAHLEN |
| 30.07 12:37 | dpa-AFX: *MERCK Q2 GAAP NET INCOME $5.455 BLN; NON-GAAP NET INCOME $5.809 BLN |
| 30.07 12:36 | dpa-AFX: *MERCK NOW EXPECTS FY NON-GAAP EPS TO BE BETWEEN $7.94 AND $8.04 |
| 30.07 12:35 | dpa-AFX: *MERCK LIFTS AND NARROWS FY WORLDWIDE SALES VIEW RANGE TO BE BETWEEN $63.4 BLN AND $64.4 BLN |
| 30.07 12:35 | dpa-AFX: *MERCK Q2 TOTAL WORLDWIDE SALES UP 7% TO $16.1 BLN |
| 30.07 12:32 | dpa-AFX: *MERCK Q2 GAAP EPS $2.14; NON-GAAP EPS $2.28 |
| 26.07 14:34 | dpa-AFX: Merck Gets Positive CHMP Opinion For Keytruda Plus Padcev To Treat Urothelial Carcinoma |
| 26.07 12:55 | dpa-AFX: *MERCK GETS POSITIVE EU CHMP OPINION FOR KEYTRUDA PLUS PADCEV IN ADVANCED UROTHELIAL CARCINOMA |
| 23.07 13:54 | dpa-AFX: Merck's Phase 2b/3 Study Of Clesrovimab To Protect Infants From RSV Disease Meets Primary Goals. |
| 23.07 12:55 | dpa-AFX: *MERCK REPORTS POSITIVE RESULTS IN PHASE 2B/3 TRIAL OF CLESROVIMAB FOR INFANT RSV PROTECTION |
| 12.07 12:47 | dpa-AFX: *MERCK COMPLETES ACQUISITION OF EYEBIO |
| 12.07 04:44 | dpa-AFX: Immutep's Eftilagimod Alfa Combination Shows Positive Phase IIb Results In Head & Neck Cancer Trial |
| 09.07 14:33 | dpa-AFX: *MERCK ANIMAL HEALTH CLOSES ACQUISITION OF ELANCO'S AQUA BUSINESS |
| 09.07 14:29 | dpa-AFX: *ELANCO COMPLETES SALE OF AQUA BUSINESS TO MERCK ANIMAL HEALTH |
| 09.07 13:40 | dpa-AFX: *PRELUDE ANNOUNCES CLINICAL COLLABORATION WITH MERCK TO EVALUATE PRT3789 WITH KEYTRUDA IN SMARCA4-MUTATED CANCERS |
| 09.07 13:40 | dpa-AFX: *PRELUDE, MERCK COLLABORATE TO EVALUATE PRT3789 - KEYTRUDA COMBINATION IN SMARCA4-MUTATED CANCERS |
|
|
